Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
9
×
Tags
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
9
×
cancer
9
×
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
9
×
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
9
×
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
clinical trials
fda
merck
pfizer
cancer immunotherapy
eli lilly
investing
nivolumab
startups
amgen
deals
What
bio
roundup
drug
annual
cancer
companies
conference
esmo
new
clinical
european
growing
medical
nash
news
oncology
society
week
advantages
alliance
alzheimer’s
appetite
approval
approved
ash
assessed
attention
bar
barcelona
biogen’s
biopharmaceutical
biotech
biotechs
black
bread
breast
brings
bristol
butter
buy
Language
unset
Current search:
photo
×
" national blog main "
×
" san diego blog main "
×
" bristol-myers squibb "
×
cancer
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M